DSIP 5 MG

Description

Delta Sleep-Inducing Peptide (DSIP): Origins and Potential Benefits

Delta sleep-inducing peptide (DSIP) is a short peptide of natural origin, first isolated in 1977 from the brains of rats during slow-wave (delta) sleep. It was named for its ability to induce sleep in animal models, particularly rabbits.

In addition to its sleep-promoting effects, DSIP has demonstrated a variety of physiological and endocrine roles. Research has shown that DSIP may:

• Regulate corticotropin (ACTH) levels
• Inhibit somatostatin secretion
• Reduce stress response
• Normalize blood pressure
• Modulate sleep cycles
• Affect pain perception

Ongoing research suggests DSIP may also be beneficial in:

• Cancer therapy
• Treatment of depression
• Protection against oxidative stress (free radical damage)

As scientific investigation continues, DSIP is emerging as a promising candidate in the development of therapies targeting neurological, cardiovascular, and endocrine disorders.

DSIP Structure

Sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
Molecular Formula: C₃₅H₄₈N₁₀O₁₅
Molecular Weight: 848.824 g/mol
PubChem CID: 68816
CAS Number: 62568-57-4
Synonyms: Emideltide, DSIP nonapeptide, Deltaran

Source: PubChem

DSIP Research

The Relationship of DSIP to Sleep

Despite its name, the connection between DSIP and sleep has proven complex and somewhat contradictory. Initial research showed that DSIP could promote sleep, but further studies have offered mixed results:

• Some studies show DSIP promotes slow-wave sleep and suppresses REM sleep.
• Others report no impact on sleep at all.
• One study found:
  • Arousal during the first hour of sleep.
  • Followed by sedation starting in the second hour[1].

Key findings in sleep research:

• DSIP appears to normalize sleep cycles and regulate dysfunction.
• In chronic insomnia:
  • DSIP improved sleep to the level of normal controls[2].
  • Reduces sleep latency and improves sleep structure[3].

Subjective human responses:

• Increased feelings of sleepiness.
• 59% increase in total sleep time versus placebo.
• Faster sleep onset[4].

⚠️ EEG data often does not reflect sedation, possibly due to outdated pharmacologic-based metrics. DSIP might help redefine how sleep is studied and measured in the lab.

DSIP Research and Chronic Pain

DSIP is gaining interest as a non-opioid pain relief alternative, particularly for chronic pain syndromes where conventional treatments fail or cause side effects.

• A small pre-clinical human trial found DSIP:
  • Reduced pain perception.
  • Improved mood.
  • Helped alleviate withdrawal symptoms in those dependent on opioids[5].

Animal research findings:

• DSIP acts on central opioid receptors.
• Produces dose-dependent analgesia[6].
• Unlike opiates, DSIP does not cause dependency.

DSIP Research and Metabolism

DSIP appears to preserve mitochondrial function during stress and hypoxia, offering significant metabolic protection:

• Prevents the shift to anaerobic respiration.
• Maintains oxidative phosphorylation under low oxygen conditions[7].
• Helps reduce toxic metabolic byproducts.

Implications:

• Potential treatment for stroke, heart attack, and ischemic injury.
• Acts as a powerful antioxidant by:
  • Preventing excessive free radical production.
  • Supporting cellular energy metabolism.

Depression, Chemical Imbalances, and DSIP

DSIP’s ability to stabilize mitochondrial activity led researchers to explore its impact on neurochemistry and mood disorders.

• DSIP helps regulate:
  • Monoamine oxidase A (MAO-A).
  • Serotonin levels[8].

Links to major depressive disorder:

• Depressed patients show lower cerebrospinal fluid levels of DSIP compared to controls[9].
• Strong connection between sleep dysfunction and depression supports DSIP’s potential role.
• May influence:
  • Hypothalamic-pituitary-adrenal (HPA) axis.
  • Suicidal behavior[10][11].

No clinical trials have yet tested DSIP as a direct treatment for depression, but its neuroregulatory role is promising for future research.

Article Author

The above literature was researched, edited, and organized by Dr. Logan, M.D.

• Doctorate: Case Western Reserve University School of Medicine
• Bachelor’s: B.S. in Molecular Biology

Scientific Journal Author

Shlomo Yehuda, Ph.D. is a leading researcher in neuroscience, thermoregulation, and peptide pharmacology.

Research highlights:

• Studied the impact of DSIP and DSIP-P under continuous light exposure in mice.
• Investigated:
  • DSIP’s role in sleep initiation.
  • Thermoregulatory effects at varying doses.
  • Pain threshold changes in light/dark cycles in rats.

Dr. Yehuda is not affiliated with Peptide Sciences, nor does he endorse any product. He is cited to acknowledge his scientific contributions to DSIP research.
Referenced in citations: [19] [20] [21] [22]

References

1. “The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep | SpringerLink.” [Online]. Available: https://link.springer.com/article/10.1007%2FBF01971753. [Accessed: 25-Jun-2019].
2. “Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia. – PubMed – NCBI.” [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmed/3622582. [Accessed: 25-Jun-2019].
3. “Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. – PubMed – NCBI.” [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmed/1299794. [Accessed: 25-Jun-2019].
4. “Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior. – PubMed – NCBI.” [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmed/6895513. [Accessed: 25-Jun-2019].
5. “Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot study. – PubMed – NCBI.” [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmed/6548970. [Accessed: 25-Jun-2019].
6. “Potent antinociceptive effect of centrally administered delta-sleep-inducing peptide (DSIP). – PubMed – NCBI.” [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmed/2853064. [Accessed: 25-Jun-2019].
7. “Delta sleep inducing peptide (DSIP): effect on respiration activity in rat brain mitochondria and stress protective potency under experimental hypo… – PubMed – NCBI.” [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmed/12668217. [Accessed: 25-Jun-2019].
8. “Effects of delta-sleep inducing peptide (DSIP) and some analogues on the activity of monoamine oxidase type A in rat brain under hypoxia stress. – PubMed – NCBI.” [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmed/7628639. [Accessed: 25-Jun-2019].
9. “Decreased concentrations of delta-sleep inducing peptide in plasma and cerebrospinal fluid from depressed patients: Nordisk Psykiatrisk Tidsskrift: Vol 39, No sup11.” [Online]. Available: https://www.tandfonline.com/doi/abs/10.3109/08039488509101959. [Accessed: 25-Jun-2019].
10. “Delta sleep-inducing peptide (DSIP): An overview of central actions and possible relationship to psychiatric illnesses: Nordisk Psykiatrisk Tidsskrift: Vol 42, No 2.” [Online]. Available: https://www.tandfonline.com/doi/abs/10.3109/08039488809103215. [Accessed: 25-Jun-2019].
11. “High delta sleep-inducing peptide-like immunoreactivity in plasma in suicidal patients with major depressive disorder. – PubMed – NCBI.” [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmed/9606527. [Accessed: 25-Jun-2019].
12. “Opioid detoxification with delta sleep-inducing peptide: results of an open clinical trial. – PubMed – NCBI.” [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmed/9617990. [Accessed: 25-Jun-2019].
13. “DSIP in the treatment of withdrawal syndromes from alcohol and opiates. – PubMed – NCBI.” [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmed/6548969. [Accessed: 25-Jun-2019].
14. “Effect of delta-sleep inducing peptide-containing preparation Deltaran on biomarkers of aging, life span and spontaneous tumor incidence in female … – PubMed – NCBI.” [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmed/12782416. [Accessed: 25-Jun-2019].
15. A. B. Sinyukhin, G. P. Timoshinov, V. A. Kornilov, and P. D. Shabanov, “P.7.a.006 Delta sleep-inducing peptide analogue corrects the CNS functional state of children treated with antiblastomic therapy,” Eur. Neuropsychopharmacol., vol. 19, pp. S681–S682, Sep. 2009.
16. E. V. Koplik et al., “Delta sleep-inducing peptide and Deltaran: potential approaches to antistress protection,” Neurosci. Behav. Physiol., vol. 38, no. 9, pp. 953–957, Nov. 2008.
17. “[DSIP: the sleep peptide or an unknown hypothalamic hormone?]. – PubMed – NCBI.” [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmed/7817664. [Accessed: 25-Jun-2019].
18. “DSIP–a tool for investigating the sleep onset mechanism: a review. – PubMed – NCBI.” [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmed/3286557. [Accessed: 25-Jun-2019].
19.  Shlomo Yehuda & Ralph L. Carasso (1987) The Effects of Dsip on Pain Threshold During Light and Dark Periods in Rats are not Naloxone-Sensitive, International Journal of Neuroscience, 37:1-2, 85-88, DOI: 10.3109/00207458708991805
20.  Graf, Markus & Christen, Heinz & Schoenenberger, Guido. (1982). DSIP/DSIP-P and circadian motor activity of rats under continuous light. Peptides. 3. 623-6. 10.1016/0196-9781(82)90161-9.
21.  Shlomo Yehuda & Ralph L. Carasso (1988) Dsip-a Tool for Investigating the Sleep Onset Mechanism: A Review, International Journal of Neuroscience, 38:3-4, 345-353, DOI: 10.3109/00207458808990695
22.  Yehuda, S., Kastin, A.J. and Coy, D.H. (1980). Thermoregulatory and locomotor effects of DSIP: Paradoxical interaction with d-amphetamine. Pharmacology Biochemistry and Behavior, [online] 13(6), pp.895–900. Available at: https://www.sciencedirect.com/science/article/pii/0091305780902257

Disclaimer

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

• The products offered on this website are intended exclusively for in-vitro research (Latin: “in glass”), meaning outside of the body.
• These products are not drugs or medications and:
  • Have not been evaluated or approved by the FDA.
  • Are not intended to diagnose, treat, cure, or prevent any disease or medical condition.
• Human or animal consumption or bodily introduction of any kind is strictly prohibited by law.

Researchers must ensure compliance with all applicable laws and guidelines regarding laboratory use.